Please login to the form below

Not currently logged in
Email:
Password:

bevacizumab

This page shows the latest bevacizumab news and features for those working in and with pharma, biotech and healthcare.

AZ, Merck’s Lynparza scores market-expanding clinical success

AZ, Merck’s Lynparza scores market-expanding clinical success

Positive phase 3 findings in ovarian cancer. Adding AstraZeneca and Merck’s Lynparza (olaparib) to Roche’s Avastin (bevacizumab) has improved outcomes in advanced ovarian cancer patients in a phase

Latest news

More from news
Approximately 21 fully matching, plus 164 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • The Biosimilar Challenge

    These include the infliximab biosimilars Inflectra and Remsima, the etanercept biosimilar Benepali (launched last year) and biosimilars to adalimumab, filgrastim and bevacizumab preparing to launch on the horizon. .

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics